Erlotinib (trade name Tarceva) is an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) in NSCLC cells and, along with gefitinib, is a first-generation TKI used to treat NSCLC with EGFR mutation [16]. Here, EGFR is linked to non-small cell lung carcinoma.